Evidence map›Paper›PMID 39266213›Full record

ArticleJournal for immunotherapy of cancer2024

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.

Stefan Barisic, Elizabeth M Brahmbhatt, Elena Cherkasova, Timothy T Spear, Ujjawal Savani, Stephanie Pierre, Gina M Scurti, Long Chen, Muna Igboko, Rosa Nadal and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03354390 (A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients With Metastatic Clear Cell Renal Cell Carcinoma), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03354390 phase1active not recruitingnot on this map

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients With Metastatic Clear Cell Renal Cell Carcinoma

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2018 to 2029Enrolled17ConditionsKidney CancerArmscell infusion
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Stefan Barisic *Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0003-4273-2907
Elizabeth M Brahmbhatt *Department of Surgery, Loyola University Chicago, Chicago, Illinois, USA.
Elena CherkasovaLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Timothy T SpearDepartment of Surgery, Loyola University Chicago, Chicago, Illinois, USA.
Ujjawal SavaniLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Stephanie PierreLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gina M ScurtiDepartment of Surgery, Loyola University Chicago, Chicago, Illinois, USA.
Long ChenLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Muna IgbokoLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Rosa NadalLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gang ZengT-Cure BioScience, Sherman Oaks, California, USA.
Gordon ParryT-Cure BioScience, Sherman Oaks, California, USA.
David F StroncekCenter for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Steven HighfillCenter for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Annika V DalheimDepartment of Surgery, Loyola University Chicago, Chicago, Illinois, USA.
Robert RegerLaboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Michael I Nishimura *Department of Surgery, Loyola University Chicago, Chicago, Illinois, USA.
Richard W Childs *Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA childsr@nhlbi.nih.gov.

Funding

Allogeneic Immunotherapy for cancer and nonmalignant hematological disordersZIAHL002345 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHILDS, RICHARD · 2009 to 2025
$53.3M
Intramural NIH HHS ZIA HL002345
6 · The paper itself

Abstract

backgroundWe discovered a novel human endogenous retrovirus (CT-RCC HERV-E) that was selectively expressed in most clear cell renal cell carcinomas (ccRCC) and served as a source of antigens for T cell-mediated killing. Here, we described the cloning of a novel T cell receptor (TCR) targeting a CT-RCC HERV-E-derived antigen specific to ccRCC and characterized antitumor activity of HERV-E TCR-transduced T cells (HERV-E T cells).

methodsWe isolated a CD8

resultsThe HLA-A11-restricted HERV-E-reactive TCR exhibited a CD8-dependent phenotype and demonstrated specific recognition of the CT-RCC-1 peptide. CD8

conclusionsThis is the first report showing that human ccRCC cells can be selectively recognized and killed by TCR-engineered T cells targeting a HERV-derived antigen. These preclinical findings provided the foundation for evaluating HERV-E TCR-transduced T cell infusions in patients with metastatic ccRCC in a clinical trial (NCT03354390).

Indexed as

Carcinoma, Renal CellEndogenous RetrovirusesKidney NeoplasmsReceptors, Antigen, T-CellAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansMiceXenograft Model Antitumor AssaysReceptors, Antigen, T-Celladoptive cell therapy - ACTkidney cancerT cell receptor - TCR

Identifiers

PMID39266213
PMCPMC11409391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.